🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Aurobindo Pharma Limited AUROPHARMA NIFTY_MIDNSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.aurobindo.com
Company Profile ↓
₹1,653.10
+56.22% 1Y
Mkt Cap₹96,012.32 Cr
P/E27.40
P/B2.54
Div. Yield0.25%
52W High₹1,717.00
52W Low₹1,022.20
Book Value₹652.39
EPS (TTM)₹60.34

Company Overview

Aurobindo Pharma Limited, a pharmaceutical company, develops, manufactures, and commercializes generic pharmaceuticals in India, the United States, Europe, and internationally. The company manufactures a range of finished formulation products in various forms, such as oral solids, liquids, injectables for generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients for CNS, anti-retroviral, cardiovascular, antibiotics, gastroenterology, anti-diabetics, and anti-allergic therapeutic areas. It also provides ointments, creams, gels, powders, transdermal, and lotions; antiretroviral drugs for PLHIV & CLHIV; and injectable products, including Penems, Penicillin, Cephalosporin, ophthalmic, inhalation, oncology, and hormone products. The company was incorporated in 1986 and is headquartered in Hyderabad, India.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 22.1% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 10.7% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 27.4, below the sector median of 41.6.

Healthy Margins

Operating margin of 15.6% supports profitability.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.21.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹33,384.74 Cr (+6.4% YoY); net profit ₹3,504.75 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +6.4%, earnings +0.5%.
  • 5-Year Trend Long-term compounding — revenue CAGR 10.7%, profit CAGR 22.1%.

Growth & Price Performance

Compounded Sales Growth

5 Years:10.69%
1 Year:6.39%

Compounded Profit Growth

5 Years:22.05%
1 Year:0.54%

Stock Price Performance

1 Year:+56.22%
6 Months:+34.19%
3 Months:+14.09%
1 Month:+4.04%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 91% of range
₹1,022.20 ₹1,717.00
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)54.80 · Neutral
Price Performance
1M+4.04%
3M+14.09%
6M+34.19%
1Y+56.22%
Valuation vs Sector

P/E of 27.40 is below the sector median of 41.64 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 10.7% over 5 years.
  • Profit CAGR of 22.1% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
27.40
Industry PE
41.64
Forward P/E
17.92
PEG Ratio
-
Book Value
₹652.39
Price to Book
2.54
P/S
2.73
EV/EBITDA
13.36
Dividend Yield
0.25%

Growth (CAGR)

Revenue 5Y
10.69%
Profit 5Y
22.05%
Revenue (YoY)
6.39%
Earnings (YoY)
0.54%

Profitability & Returns

ROCE
13.50%
ROE
9.25%
ROA
5.99%
Profit Margin
10.50%
Op Margin
15.55%
Gross Margin
57.09%
EPS (Latest Qtr)
₹17.86
EPS (TTM)
₹60.34

Balance Sheet & Liquidity

Debt/Equity
0.21
Quick Ratio
1.15
Current Ratio
1.81
Debt
₹8,072.84 Cr
Total Assets
₹58,502.15 Cr
Current Assets
₹32,708.75 Cr
Working Capital
₹14,669.74 Cr

Ownership

Promoter Holding
54.78%
Chg in Prom Hold
-
FII / Inst Holding
30.57%
Chg in FII Hold
0.12%

Financial Snapshot

Enterprise Value
₹96,012.32 Cr
Total Revenue (TTM)
₹33,384.74 Cr
EBITDA
₹7,224.81 Cr
Free Cash Flow
₹2,421.70 Cr
Operating Cash Flow
₹5,526.37 Cr
Shares Outstanding
₹58.08 Cr
Gross Margin
57.09%
Payout Ratio
6.63%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 AUROPHARMA Aurobindo Pharma Limited NIFTY_MIDNSEPHARMA 1,653.10 27.40 ₹96,012.32 Cr 0.25% 13.50% 9.25% 10.69% 22.05%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,899.00 39.73 ₹4.56 L Cr 0.82% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,100.00 94.06 ₹2.42 L Cr 0.36% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,857.00 75.99 ₹1.64 L Cr 0.77% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,650.00 64.10 ₹1.24 L Cr 0.22% 19.20% 20.48% 14.85% 33.34%
6 LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA 684.90 236.17 ₹1.19 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,120.00 22.36 ₹1.13 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,385.00 28.85 ₹1.12 L Cr 0.88% 14.86% 11.27% 7.23% 11.45%
9 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 1,840.00 111.85 ₹99,333.61 Cr 0.13% 19.53% 16.77% 3.77% 4.00%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue 6,473.00 Cr6,851.00 Cr7,219.00 Cr7,352.00 Cr7,580.00 Cr7,567.00 Cr--8,381.12 Cr7,791.77 Cr8,286.00 Cr8,604.51 Cr8,751.50 Cr9,105.82 Cr
Cost of Revenue --------3,427.88 Cr3,239.22 Cr-3,481.21 Cr3,429.07 Cr3,626.95 Cr
Gross Profit --------4,953.24 Cr4,552.55 Cr-5,123.30 Cr5,322.43 Cr5,478.87 Cr
Operating Expenses 5,477.00 Cr5,702.00 Cr5,846.00 Cr5,753.00 Cr5,920.00 Cr5,949.00 Cr--3,605.75 Cr3,354.83 Cr6,608.00 Cr3,814.69 Cr4,000.06 Cr4,084.63 Cr
Operating Income 650.00 Cr822.00 Cr955.00 Cr1,176.00 Cr1,306.00 Cr1,214.00 Cr--1,347.49 Cr1,197.72 Cr1,249.00 Cr1,308.61 Cr1,322.37 Cr1,394.24 Cr
EBITDA 996.00 Cr1,149.00 Cr1,373.00 Cr1,599.00 Cr1,660.00 Cr1,618.00 Cr--1,894.54 Cr1,710.25 Cr1,678.00 Cr1,896.02 Cr1,867.39 Cr2,103.57 Cr
Interest Expense 56.00 Cr57.00 Cr68.00 Cr76.00 Cr89.00 Cr111.00 Cr--115.02 Cr97.75 Cr95.00 Cr92.77 Cr98.21 Cr101.66 Cr
Pretax Income 730.00 Cr812.00 Cr1,076.00 Cr1,262.00 Cr1,230.00 Cr1,324.00 Cr--1,335.09 Cr1,206.80 Cr1,276.00 Cr1,338.52 Cr1,290.61 Cr1,515.09 Cr
Tax Provision 226.30 Cr243.60 Cr322.80 Cr328.12 Cr319.80 Cr410.44 Cr--432.26 Cr382.60 Cr433.84 Cr428.72 Cr369.77 Cr483.06 Cr
Net Income 506.00 Cr570.00 Cr752.00 Cr940.00 Cr907.00 Cr918.00 Cr--903.47 Cr824.75 Cr848.00 Cr910.29 Cr921.26 Cr1,032.56 Cr
Diluted EPS 8.649.7412.9215.9815.5115.69--15.5614.2014.6115.6715.8617.86

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 12,103.00 Cr13,772.00 Cr14,910.00 Cr16,463.00 Cr19,564.00 Cr23,099.00 Cr24,775.00 Cr-24,617.13 Cr28,704.50 Cr31,378.13 Cr33,384.74 Cr
Cost of Revenue --------11,899.70 Cr13,236.21 Cr13,741.52 Cr14,324.93 Cr
Gross Profit --------12,717.43 Cr15,468.29 Cr17,636.61 Cr19,059.81 Cr
Operating Expenses 9,524.00 Cr10,579.00 Cr11,469.00 Cr12,691.00 Cr15,612.00 Cr18,249.00 Cr19,497.00 Cr-10,179.83 Cr11,026.76 Cr12,588.55 Cr13,866.94 Cr
Operating Income 2,246.00 Cr2,801.00 Cr3,013.00 Cr3,214.00 Cr3,284.00 Cr3,882.00 Cr4,223.00 Cr-2,537.60 Cr4,441.53 Cr5,048.06 Cr5,192.87 Cr
EBITDA 2,579.00 Cr3,193.00 Cr3,441.00 Cr3,772.00 Cr3,952.00 Cr4,849.00 Cr5,278.00 Cr-3,986.03 Cr6,139.99 Cr7,097.88 Cr7,224.81 Cr
Interest Expense 160.00 Cr257.00 Cr67.00 Cr78.00 Cr263.00 Cr305.00 Cr74.00 Cr-128.95 Cr268.09 Cr440.39 Cr352.31 Cr
Pretax Income 2,168.00 Cr2,744.00 Cr3,061.00 Cr3,241.00 Cr3,091.00 Cr3,743.00 Cr7,344.00 Cr-2,612.50 Cr4,379.99 Cr5,066.29 Cr5,111.85 Cr
Tax Provision 607.04 Cr713.44 Cr765.25 Cr810.25 Cr741.84 Cr898.32 Cr1,982.88 Cr-684.85 Cr1,211.02 Cr1,582.72 Cr1,608.88 Cr
Net Income 1,571.00 Cr2,024.00 Cr2,301.00 Cr2,423.00 Cr2,364.00 Cr2,844.00 Cr5,334.00 Cr-1,927.50 Cr3,172.97 Cr3,485.88 Cr3,504.75 Cr
Diluted EPS 26.9834.6139.2941.3640.3648.5691.0545.1932.9054.1659.8160.34

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 12,910.00 Cr15,896.00 Cr16,200.00 Cr20,942.00 Cr26,271.00 Cr28,765.00 Cr33,416.00 Cr-39,889.99 Cr45,071.51 Cr49,784.97 Cr58,502.15 Cr
Current Assets --------21,545.67 Cr24,205.63 Cr27,162.46 Cr32,708.75 Cr
Cash & Equivalents --------4,396.29 Cr3,393.48 Cr5,568.95 Cr7,191.40 Cr
Inventory --------8,511.23 Cr9,808.23 Cr10,543.72 Cr12,052.94 Cr
Receivables --------4,466.38 Cr4,816.74 Cr5,745.93 Cr7,094.37 Cr
Total Liabilities --------13,038.14 Cr15,220.71 Cr17,138.04 Cr20,619.34 Cr
Current Liabilities --------11,493.78 Cr12,199.13 Cr14,682.34 Cr18,039.01 Cr
Long Term Debt --------618.96 Cr2,134.90 Cr1,561.65 Cr802.75 Cr
Total Debt 4,451.00 Cr5,041.00 Cr3,364.00 Cr4,770.00 Cr6,967.00 Cr5,826.00 Cr5,339.00 Cr-5,286.21 Cr6,647.63 Cr8,262.87 Cr8,072.84 Cr
Total Equity 5,156.00 Cr7,288.00 Cr9,372.00 Cr11,681.00 Cr13,891.00 Cr16,825.00 Cr21,930.00 Cr-26,839.85 Cr29,842.80 Cr32,653.32 Cr37,890.97 Cr
Shares Outstanding --------58.59 Cr58.59 Cr58.08 Cr58.08 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 1,237.00 Cr1,420.00 Cr3,279.00 Cr1,955.00 Cr1,651.00 Cr4,381.00 Cr3,329.00 Cr-2,386.75 Cr2,434.52 Cr3,924.62 Cr5,526.37 Cr
Investing Cash Flow -1,017.00 Cr-1,446.00 Cr-1,787.00 Cr-1,927.00 Cr-2,904.00 Cr-1,563.00 Cr597.00 Cr--3,977.75 Cr-4,255.95 Cr-1,875.80 Cr-3,458.61 Cr
Financing Cash Flow 93.00 Cr365.00 Cr-1,915.00 Cr864.00 Cr1,919.00 Cr-1,947.00 Cr-1,365.00 Cr-1,814.41 Cr800.42 Cr119.78 Cr-1,269.15 Cr
Capital Expenditure -746.00 Cr-1,566.00 Cr-1,685.00 Cr-1,241.00 Cr-1,537.00 Cr-1,412.00 Cr-1,826.00 Cr--2,720.40 Cr-3,561.50 Cr-2,519.55 Cr-3,104.67 Cr
Free Cash Flow 491.00 Cr-146.00 Cr1,594.00 Cr714.00 Cr114.00 Cr2,969.00 Cr1,503.00 Cr--333.65 Cr-1,126.98 Cr1,405.07 Cr2,421.70 Cr
Net Change in Cash 313.00 Cr340.00 Cr-424.00 Cr892.00 Cr666.00 Cr871.00 Cr2,561.00 Cr-223.41 Cr-1,021.01 Cr2,168.60 Cr798.61 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------51.7%53.9%56.2%57.1%
Operating Margin % 18.6%20.3%20.2%19.5%16.8%16.8%17.0%-10.3%15.5%16.1%15.6%
Net Margin % 13.0%14.7%15.4%14.7%12.1%12.3%21.5%-7.8%11.1%11.1%10.5%
ROE % 30.5%27.8%24.6%20.7%17.0%16.9%24.3%-7.2%10.6%10.7%9.2%
ROCE % --------8.9%13.5%14.4%12.8%

Shareholding Pattern

Insiders
54.78%
Institutions
30.57%
Public Float
67.61%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for AUROPHARMA

Google News hu, 20 Aug 2026

Aurobindo Pharma (NSEI:AUROPHARMA) Stock Sees Modest Fair Value Lift On Revised Assumptions - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxONlMyYkVKVzdsRmJHaWVZOXJORjc4R1IyNl9tRFo1eE9uMFVzMWlYR2V4VGcwUlFXSnFicjZlTXFMR3hMRm01aGZ1NVY3OXE2MTB2S091YXhhSTZOY2w3elJNNUdMQ3N1V3JqQlF4azJyS25DUzByREY3OEJmS3VTODA5cy1MTnhZVFhOVU…

Google News Wed, 05 Aug 2026

Aurobindo Pharma (NSEI:AUROPHARMA) Stock Sees Modest Fair Value Lift As Analysts Rework Assumptions - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxOdDc1S0lGZ1ByMjk2djBaRHpmUUp5bGpzOWVvaVphdWF1dEtuTUpFRHhOckJ1TThiWl9HSTdBNHB5NUo1aU1vSXlNTkU3NkJjdmp6UUI2dkRkU1psOHJoS3RPdEFrMHlGUzJBWGFucjAyWjlQUHltTTJWQmtfcGlXVUVYZkVVZXRPYnBYUk…

Google News Mon, 31 Aug 2026

Aurobindo Pharma shares down on three observations from USFDA - TradingView

<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxOWFpEY0tPY3J4X0VySHFYdXVyY3JhQ1Q4ZVN3V2kzNVNpNnM2TmZRRnVyYU1kLWtxc2UydlplVFZnYWpQUXhYVXYyWlduNWZiMFMwRXpWRWo5LVhKTEM5cnRvLXhDTGM2V2NnNkJrUTZrRXVrVF9tY0k5WFI2bTlWVmV2c3BWeWdWb2Vhek…

Google News Fri, 28 Aug 2026

AUROPHARMA Outlook for the Week - equitypandit.com

<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE85VGRkV1plUkNBVGZzVDJpMDNBY1NyS0syOXpOTTRTZW90QWs2WkJqNWRYd2xCUkNyRzBTTlVEV1lzRUN4ZHNaQjUxUDE5TFpiVk5HbjRLRFRoSlNNN1plSmhKcExxVERkd0VNOEFB?oc=5" target="_blank">AUROPHARMA Outlook …

Google News Wed, 08 Jul 2026

Aurobindo Pharma (NSEI:AUROPHARMA) Stock Sees Fair Value Lift On Stronger Growth Assumptions - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxOeXNyM24yNUl3bHU0WnVlTnMyUmxFQlEyZEZlS3dPdks5X1pDNDJ4VjVZX0xZMUdPVXBMcHhmVW5VT2ZBMjNEekdlZHAxd0FubTdYNWdZZmN5a29Sa2VhbXZpT1R4OUFnV1h5VkNHRklUNHpObUoyY3Y1blR4TlBaZnFiUllqY3czd0hoS0…

Google News Sat, 08 Aug 2026

Results: Aurobindo Pharma Limited Exceeded Expectations And The Consensus Has Updated Its Estimates - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxQS1RycHFpSldMb0VPU2NUZGRwTkRqYlg5YjdheHpjQ2ltZ1QzV0NYVERpU0NNNGVIUHNFZWllOVlEcHVxUENLTk81R19iS24xUXA3S2ttN1FuQU5mSjZPTzRZWk5Kc2VyZl9WeUNwUDdROXMxTnRHQ3VYX1IzcWRNZHdqTk9ZNGhBOG9URF…

AUROPHARMA — Frequently Asked Questions

What is the current share price of Aurobindo Pharma Limited (AUROPHARMA)?

As of 2026-09-08 04:53 IST, Aurobindo Pharma Limited (AUROPHARMA) trades at ₹1,653.10 on NSE. Its 52-week range is ₹1,022.20 to ₹1,717.00.

What is the market capitalisation of AUROPHARMA?

Aurobindo Pharma Limited (AUROPHARMA) has a market capitalisation of ₹96,012.32 Cr on NSE.

What is the P/E ratio of AUROPHARMA?

AUROPHARMA trades at a trailing price-to-earnings (P/E) ratio of 27.40. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 2.54.

Does AUROPHARMA pay a dividend?

Aurobindo Pharma Limited (AUROPHARMA) currently offers a dividend yield of 0.25%.

What is the return on equity (ROE) of AUROPHARMA?

AUROPHARMA has a return on equity (ROE) of 9.25%. Its return on capital employed (ROCE) is 13.50%.

Is AUROPHARMA a good stock to buy?

This page provides a data-driven analysis of Aurobindo Pharma Limited (AUROPHARMA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space